NCT06136897 2026-03-18
Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
240 trialsNCT03523585 2026-02-27
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
Daiichi Sankyo
Phase 3 Completed
NCT03179904 2026-02-24
TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer
Mayo Clinic
Phase 2 Active not recruiting
NCT04430738 2026-02-24
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Seagen Inc.
Phase 2 Active not recruiting
NCT04024462 2026-02-20
A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT01853748 2026-02-19
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01196390 2026-02-18
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT02226276 2026-02-13
Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer
City of Hope Medical Center
Phase NA Active not recruiting
NCT03101748 2026-02-12
Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT03365882 2026-02-10
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
SWOG Cancer Research Network
Phase 2 Completed
NCT05415215 2026-02-10
ProHer
Hoffmann-La Roche
Phase 3 Completed
NCT01796197 2026-02-05
Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa
Dana-Farber Cancer Institute
Phase 2 Completed
NCT04661150 2026-01-30
A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT03879577 2026-01-21
Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer
University of Chicago
Phase 2 Active not recruiting
NCT04721977 2026-01-09
MK-7119-001
Pfizer
Phase 2 Active not recruiting
NCT04578106 2026-01-06
ELPIS
Fundacio Clinic Barcelona
Phase 2 Terminated
NCT03199885 2025-12-30
Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT03095352 2025-12-22
Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease
University of California, San Francisco
Phase 2 Completed
NCT01358877 2025-11-28
APHINITY
Hoffmann-La Roche
Phase 3 Completed
NCT01750073 2025-11-18
Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer
University of Nebraska
Phase 2 Active not recruiting
NCT04425018 2025-11-18
MARGOT
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT02827877 2025-11-14
Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT01191697 2025-11-03
CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03501979 2025-08-29
Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD
University of Alabama at Birmingham
Phase 2 Terminated
NCT00770809 2025-08-15
Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery
National Cancer Institute (NCI)
Phase 3 Completed
NCT01772472 2025-07-22
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)
Hoffmann-La Roche
Phase 3 Completed
NCT01275677 2025-07-14
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT03414658 2025-07-02
The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT01937117 2025-07-01
Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT03094052 2025-06-26
Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib
University of California, San Francisco
Phase 2 Completed
NCT03767335 2025-06-26
B-PRECISE-01
Menarini Group
Phase 1 Completed
NCT00769379 2025-06-12
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy
National Cancer Institute (NCI)
Phase 3 Completed
NCT01273610 2025-06-10
Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT04082364 2025-06-08
MAHOGANY
MacroGenics
Phase 2/3 Completed
NCT02091960 2025-04-04
A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer
Astellas Pharma Inc
Phase 2 Completed
NCT03417544 2025-04-02
Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT00520975 2025-03-28
Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU
National Cancer Institute (NCI)
Phase 3 Terminated
NCT00490139 2025-03-21
ALTTO
Novartis
Phase 3 Completed
NCT00667251 2025-03-21
Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer
Novartis
Phase 3 Completed
NCT02492711 2025-03-17
SOPHIA
MacroGenics
Phase 3 Completed
NCT01160211 2025-03-07
A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer
Novartis
Phase 3 Completed
NCT01084876 2025-02-11
Compare
Celltrion
Phase 3 Completed
NCT01649271 2025-02-11
Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.
Boehringer Ingelheim
Phase 1 Completed
NCT00950742 2025-02-10
Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With HerceptinĀ® in Patients With HER2-positive Advanced Breast Cancer.
Boehringer Ingelheim
Phase 1 Completed
NCT01084863 2025-01-24
Compare
Celltrion
Phase 1/2 Completed
NCT04499924 2025-01-22
MOUNTAINEER-02
Seagen Inc.
Phase 2/3 Completed
NCT00470704 2024-12-19
Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03644186 2024-12-13
TOUCH
ETOP IBCSG Partners Foundation
Phase 2 Completed
NCT02675231 2024-11-26
monarcHER
Eli Lilly and Company
Phase 2 Completed
NCT03043313 2024-11-26
Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer
Seagen Inc.
Phase 2 Completed